Price T Rowe Associates Inc Merus N.V. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Merus N.V. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 1,281,980 shares of MRUS stock, worth $59.7 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,281,980
Previous 1,385,216
7.45%
Holding current value
$59.7 Million
Previous $82 Million
21.86%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding MRUS
# of Institutions
200Shares Held
61.9MCall Options Held
243KPut Options Held
300K-
Rtw Investments, LP New York, NY4.17MShares$194 Million3.32% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.41MShares$159 Million3.17% of portfolio
-
Commodore Capital LP New York, NY3.35MShares$156 Million14.22% of portfolio
-
Wellington Management Group LLP Boston, MA2.89MShares$135 Million0.03% of portfolio
-
Samlyn Capital, LLC New York, NY2.61MShares$122 Million2.1% of portfolio
About Merus N.V.
- Ticker MRUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,878,200
- Market Cap $2.14B
- Description
- Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...